Compare Heron Therapeutics Inc (HRTX) vs Kroger Co (KR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Kroger Co — how do they compare? Heron Therapeutics Inc trades at $0.37 (market cap $74.04M), while Kroger Co trades at $61.26 (market cap $34.99B). The key difference: Kroger Co is far larger — about 472.6× Heron Therapeutics Inc's market cap, and Kroger Co pays a 2.63% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Kroger Co for 108 Days on average.
| HRTX | KR | |
|---|---|---|
Market Cap | $74.04M | $34.99B |
Volume | 3,668,095 | 8,938,607 |
Sector | Health | Consumer Staples |
52-Week High | $1.49 | $75.60 |
52-Week Low | $0.27 | $55.53 |
Typical Hold Time | 35 Days | 108 Days |
Enterprise Value | $180.78M | $56.41B |
Dividend Yield | — | 2.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.39, up 17.58% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings performance discussions.
The outlook is mixed: strong analyst support and technical momentum suggest potential upside, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on revenue growth translating to profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
Kroger (KR) trades at $59.25, up 1.44% with a bullish technical signal. The stock shows strong fundamentals with $147.12B revenue and $2.67B net income for 2025, supported by positive cash flow trends. Recent earnings beat expectations in two of the last three quarters, while analysts maintain a Moderate Buy consensus with a $70.62 price target. The company continues digital growth initiatives and maintains dividend payments.
Kroger presents a value opportunity with low P/S ratio (0.25) and consistent profitability, though near-term risks include integration challenges from acquisitions and softer sales guidance. The stock's current price near support at $58 offers potential upside to analyst targets, balanced by competitive pressures in the grocery sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Kroger Co
Kroger is the leading American grocer, with 2,726 supermarkets operating under several banners throughout the country as of the end of fiscal 2021. Around 83% of stores have pharmacies, while nearly 60% also sell fuel. The company also operates roughly 120 fine jewelry stores. Kroger features a leading private-label offering and manufactures around 30% of its own-brand units (and more than 40% of its grocery own-label assortment) itself, in 33 food production plants nationwide. Kroger is a top-two grocer in most of its major markets (as of early 2021, according to company data). Virtually all of Kroger's sales come from the United States.
Read more on KR →
